The market has been down on Crispr Therapeutics AG (CRSP) stock recently. CRSP gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CRSP Stock Today?
Crispr Therapeutics AG (CRSP) stock is higher by 3.1% while the S&P 500 is lower by -0.17% as of 3:04 PM on Tuesday, Mar 30. CRSP has gained $3.43 from the previous closing price of $110.72 on volume of 951,502 shares. Over the past year the S&P 500 has gained 50.93% while CRSP has gained 157.73%. CRSP lost -$5.29 per share in the over the last 12 months.
More About Crispr Therapeutics AG
CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.